TADCLOT- a Double Blind Randomized Controlled Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

2,200

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

February 20, 2025

Study Completion Date

February 20, 2025

Conditions
Stent ThrombosisMyocardial Infarction, Acute
Interventions
DRUG

Ticagrelor 90 MG

Patients in the treatment group will receive Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.

DRUG

Clopidogrel

Patients in the control group will receive Clopidogrel 600 mg as a loading dose and 75 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.

Trial Locations (1)

755000

National Institute of Cardiovascular Diseases, Karachi

All Listed Sponsors
collaborator

PharmEvo Pvt Ltd

INDUSTRY

lead

National Institute of Cardiovascular Diseases, Pakistan

OTHER

NCT06318481 - TADCLOT- a Double Blind Randomized Controlled Trial | Biotech Hunter | Biotech Hunter